These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 20192803)

  • 1. From allergen genes to allergy vaccines.
    Valenta R; Ferreira F; Focke-Tejkl M; Linhart B; Niederberger V; Swoboda I; Vrtala S
    Annu Rev Immunol; 2010; 28():211-41. PubMed ID: 20192803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?
    Tulaeva I; Kratzer B; Campana R; Curin M; van Hage M; Karsonova A; Riabova K; Karaulov A; Khaitov M; Pickl WF; Valenta R
    Front Immunol; 2020; 11():1368. PubMed ID: 32733455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant allergy vaccines based on allergen-derived B cell epitopes.
    Valenta R; Campana R; Niederberger V
    Immunol Lett; 2017 Sep; 189():19-26. PubMed ID: 28472641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Aspects of Allergens and Allergy.
    Valenta R; Karaulov A; Niederberger V; Gattinger P; van Hage M; Flicker S; Linhart B; Campana R; Focke-Tejkl M; Curin M; Eckl-Dorna J; Lupinek C; Resch-Marat Y; Vrtala S; Mittermann I; Garib V; Khaitov M; Valent P; Pickl WF
    Adv Immunol; 2018; 138():195-256. PubMed ID: 29731005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Molecular Allergen Recognition Profile in China as Basis for Allergen-Specific Immunotherapy.
    D'souza N; Weber M; Sarzsinszky E; Vrtala S; Curin M; Schaar M; Garib V; Focke-Tejkl M; Li Y; Jones R; Chen H; Valenta R; Sun B
    Front Immunol; 2021; 12():719573. PubMed ID: 34512644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.
    Valenta R; Campana R; Focke-Tejkl M; Niederberger V
    J Allergy Clin Immunol; 2016 Feb; 137(2):351-7. PubMed ID: 26853127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic allergen modification in the development of novel approaches to specific immunotherapy.
    Mutschlechner S; Deifl S; Bohle B
    Clin Exp Allergy; 2009 Nov; 39(11):1635-42. PubMed ID: 19624521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
    Focke M; Swoboda I; Marth K; Valenta R
    Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategies for allergen immunotherapy.
    Carnés J; Robinson DS
    Recent Pat Inflamm Allergy Drug Discov; 2008 Jun; 2(2):92-101. PubMed ID: 19075996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines for allergy.
    Linhart B; Valenta R
    Curr Opin Immunol; 2012 Jun; 24(3):354-60. PubMed ID: 22521141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance.
    Campana R; Huang HJ; Freidl R; Linhart B; Vrtala S; Wekerle T; Karaulov A; Valenta R
    Semin Immunol; 2017 Apr; 30():67-80. PubMed ID: 28939389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From allergen structure to new forms of allergen-specific immunotherapy.
    Valenta R; Kraft D
    Curr Opin Immunol; 2002 Dec; 14(6):718-27. PubMed ID: 12413521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bypassing IgE and targeting T cells for specific immunotherapy of allergy.
    Akdis CA; Blaser K
    Trends Immunol; 2001 Apr; 22(4):175-8. PubMed ID: 11274910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunoglobulin E-allergen interaction: a target for therapy of type I allergic diseases.
    Valenta R; Almo S; Ball T; Dolecek C; Steinberger P; Laffer S; Eibensteiner P; Flicker S; Vrtala S; Spitzauer S; Valent P; Denepoux S; Kraft D; Banchereau J; Lebecque S
    Int Arch Allergy Immunol; 1998 Jul; 116(3):167-76. PubMed ID: 9693264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renaissance of the blocking antibody concept in type I allergy.
    Flicker S; Valenta R
    Int Arch Allergy Immunol; 2003 Sep; 132(1):13-24. PubMed ID: 14555854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.
    Linhart B; Valenta R
    Vaccine; 2012 Jun; 30(29):4328-35. PubMed ID: 22100888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biotechnology-based allergy diagnosis and vaccination.
    Bhalla PL; Singh MB
    Trends Biotechnol; 2008 Mar; 26(3):153-61. PubMed ID: 18222557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis.
    Westwood M; Ramaekers B; Lang S; Armstrong N; Noake C; de Kock S; Joore M; Severens J; Kleijnen J
    Health Technol Assess; 2016 Sep; 20(67):1-178. PubMed ID: 27623692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope peptides and immunotherapy.
    Tanabe S
    Curr Protein Pept Sci; 2007 Feb; 8(1):109-18. PubMed ID: 17305564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal Nanoemulsion Allergy Vaccine Suppresses Alarmin Expression and Induces Bystander Suppression of Reactivity to Multiple Food Allergens.
    Farazuddin M; Landers JJ; Janczak KW; Lindsey HK; Finkelman FD; Baker JR; O'Konek JJ
    Front Immunol; 2021; 12():599296. PubMed ID: 33717078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.